Abstract: The present invention relates to the development of polypeptides useful for the treatment of diseases associated with amyloid deposits, and more specifically for the treatment of Alzheimer's disease. The invention also relates to compositions comprising the developed polypeptides and to a method for the identification of compounds useful for the treatment of diseases associated with the formation of amyloid deposits.

Abstract: The invention relates to the use of morin and mangiferin, the pharmaceutically acceptable salts, prodrugs and/or solvates thereof in the production of a pharmaceutical composition for the prevention and/or treatment of a neurodegenerative disease and symptoms associated with ageing, as well as to food compositions comprising said compounds.

Abstract: The present invention refers to the use of glutamate transporters, glutamate and EGF to detect the presence of demyelinating diseases in a subject, to determine the status or severity of the same or to monitor the effects of a therapy administered to a subject who suffers from such diseases; to the use of the said markers for the searching, identification, development and evaluation of the efficacy of compounds for the treatment of such diseases, with a view to developing new drugs; to the use of compounds which promote the expression of the EAAT1 and EAAT2 transporters, as well as EGF for the treatment of demyelinating diseases. In a preferred embodiment, the methods and compounds of the invention are applicable to MS.

Abstract: The invention describes an in vitro method for detecting a psychiatric disorder occurring with psychosis selected from schizophrenia and bipolar disorder in an individual who has suffered a first psychotic episode, or for determining the state or severity of said disorder, or for monitoring the effect of a therapy administered to an individual who suffers said disorder, or for evaluating the predisposition of an individual presenting a prodromal symptom to develop said disorder, based on the use of the brain-derived neutrophic factor (BDNF) as a marker.

Abstract: The invention relates to the use of morin and mangiferin, the pharmaceutically acceptable salts, prodrugs and/or solvates thereof in the production of a pharmaceutical composition for the prevention and/or treatment of a neurodegenerative disease and symptoms associated with ageing, as well as to food compositions comprising said compounds.

Abstract: The present invention refers to the use of glutamate transporters, glutamate and EGF to detect the presence of demyelinating diseases in a subject, to determine the status or severity of the same or to monitor the effects of a therapy administered to a subject who suffers from such diseases; to the use of the said markers for the searching, identification, development and evaluation of the efficacy of compounds for the treatment of such diseases, with a view to developing new drugs; to the use of compounds which promote the expression of the EAAT1 and EAAT2 transporters, as well as EGF for the treatment of demyelinating diseases. In a preferred embodiment, the methods and compounds of the invention are applicable to MS.

Abstract: The present invention refers to an in vitro method for detecting the presence of demyelinating diseases in an individual, for determining the stage or severity of said diseases in the individual, or for monitoring the effect of the therapy administered to an individual suffering said diseases; to the search, identification, development and evaluation of efficacy of compounds for therapy of said diseases for the purpose of developing new drugs; as well as to agents inhibiting DUSP6 protein expression and/or activity, and/or the effects of this expression. The methods and agents of the invention are preferably applied to multiple sclerosis.

Abstract: The present invention is related to the treatment of demyelinating and autoimmune diseases, more particularly with the treatment of multiple sclerosis. The treatment consists of the administration of P2X purinergic receptors antagonist substances which cause a remission of the symptoms common to these types of diseases. This is demonstrated in in vitro cell models as well as in animal models.